


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WLS Holdings Limited
滙隆控股有限公司*

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 8021)

**VOLUNTARY ANNOUNCEMENT –
STRATEGIC COOPERATION AGREEMENT**

This voluntary announcement is made by WLS Holdings Limited (“**Company**”, together with its subsidiaries, the “**Group**”) to provide information on the latest business development of the Group to the shareholders of the Company and potential investors.

ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT

The board of directors of the Company (the “**Board**”) is pleased to announce that on 14 June 2022, the Company entered into a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with Zhejiang Hengting Biotechnology Limited (浙江恒婷生物科技有限公司) (“**Hengting Biotechnology**”).

According to the Strategic Cooperation Agreement, both parties have tentatively agreed that the Company and Hengting Biotechnology, together with its subsidiaries (collectively the “**Hengting Biotechnology Group**”), will jointly develop or adopt other forms of cooperation to (i) establish a marketing company and an appraisal centre for Xiu Jiang wine and set up channels for agents, and fully penetrate into the mainland wine market and build the Xiu Jiang wine’s own brand; (ii) fully expand the mainland market for skin care products through the cooperation in selling the proprietary high-end and high-tech skin care products of Hengting Biotechnology Group at an appropriate time. Both parties will develop a comprehensive strategic cooperation based on the principle of long-term strategic cooperation, including but not limited to equity investment, debt investment and other investments. Both parties will continue to expand the scope of cooperation according to market conditions and may hold senior management meetings from time to time to discuss the mode, direction and progress of the cooperation and other matters relating to the cooperation projects.

* *For identification purpose only*

To the best of the Board’s knowledge, information and belief, having made all reasonable enquiries, Hengting Biotechnology Group and its ultimate beneficial owners are independent third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”)).

REASONS FOR ENTERING INTO THE STRATEGIC COOPERATION AGREEMENT

Under the framework of the Strategic Cooperation Agreement, the Company and Hengting Biotechnology Group will strengthen the exchange and collaboration in various aspects such as business opportunities and market information for mutual complementary and sharing purposes. Both parties will work closely with each other in the areas of the development of Chinese wine as well as high-end and high-tech skin care products in an active manner.

ABOUT HENGTING BIOTECHNOLOGY GROUP

The principal business of Hengting Biotechnology Group is to (i) develop the scientific research, production and sales of general health products, and introduce a number of renowned domestic enterprises as strategic partners for establishing a comprehensive health products platform; (ii) establish an appraisal centre for Xiu Jiang wine and sell Xiu Jiang wine through the channels of its own marketing companies and agents; (iii) sell proprietary high-end and high-tech skin care products of Hengting Biotechnology Group.

Meanwhile, Hengting Biotechnology has also reached cooperation with famous internet medical health service brands to further enhance the level of digitalization, intelligence and international development, and facilitate the innovative technology, so as to create more potential comprehensive health industry clusters.

As of the date of this announcement, according to the Strategic Cooperation Agreement, the specific business cooperation and cooperation mode between the two parties in the future will be agreed upon by both parties through mutual consultation and a formal cooperation agreement will be signed separately after the approval in accordance with relevant laws and regulations and their respective procedures.

The Board reminds the shareholders of the Company and potential investors that the transaction under the Strategic Cooperation Agreement may be conditional upon the conclusion of the final agreement and the fulfilment of conditions precedent.

As the Company may or may not pursue the abovementioned business opportunity, shareholders of the Company and potential investors are advised to note that the relevant transactions may or may not proceed. The Company will make further announcements on the development of the project under the Strategic Cooperation Agreement in due course in accordance with the GEM Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
WLS Holdings Limited
So Yu Shing
Chairman

Hong Kong, 14 June 2022

As at the date of this announcement, the Board comprises Dr. So Yu Shing (Chairman and Executive Director), Mr. Kong Kam Wang (Executive Director and Chief Executive Officer), Ms. Lai Yuen Mei, Rebecca (Executive Director), Mr. So Wang Chun, Edmond (Executive Director), Mr. Tse Fung Chun (Executive Director), Mr. Law Man Sang (Independent Non-executive Director), Ms. Lam Wai Yu (Independent Non-executive Director) and Mr. Lo Ka Ki (Independent Non-executive Director).

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Listed Company Information” page for at least 7 days from the date of its posting and on the website of the Company at www.wls.com.hk.